Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Moleculin Biotech (MBRX) EPS (Basic) (2016 - 2025)

Moleculin Biotech (MBRX) has 10 years of EPS (Basic) data on record, last reported at -$0.46 in Q3 2025.

  • For Q3 2025, EPS (Basic) rose 75.66% year-over-year to -$0.46; the TTM value through Sep 2025 reached -$1.81, up 91.49%, while the annual FY2024 figure was -$6.32, 58.06% up from the prior year.
  • EPS (Basic) reached -$0.46 in Q3 2025 per MBRX's latest filing, up from -$1.27 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.55 in Q4 2024 and bottomed at -$14.44 in Q4 2022.
  • Average EPS (Basic) over 5 years is -$2.57, with a median of -$0.63 recorded in 2025.
  • Peak YoY movement for EPS (Basic): crashed 15944.44% in 2022, then soared 103.82% in 2024.
  • A 5-year view of EPS (Basic) shows it stood at -$0.09 in 2021, then plummeted by 15944.44% to -$14.44 in 2022, then grew by 0.21% to -$14.41 in 2023, then skyrocketed by 103.82% to $0.55 in 2024, then plummeted by 183.64% to -$0.46 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Basic) were -$0.46 in Q3 2025, -$1.27 in Q2 2025, and -$0.63 in Q1 2025.